$NTRA

Marcus Gail Boxer sold $2.4M of NTRA

Marcus Gail Boxer sold 11,000 shares of Natera, Inc. (NTRA) at an average of $217.21 ($216.06–$218.82, $2.39M total) across 4 trades on 2026-06-05.

Original reporting
SEC EDGAR · Marcus Gail Boxer
Published Jun 10, 2026, 1:05 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 10, 2026, 1:31 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$NTRA
Neutral
medium confidence
Mentioned
$NTRA
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NTRANeutralLow
01

Why it matters

The only new fact is the director’s sale size, price range, and post-transaction holdings; it does not include any new company performance, guidance, or regulatory/product developments.

02

Market read

Traders may treat this as a mild sentiment datapoint, but it is unlikely to drive a sustained repricing without additional company catalysts.

03

What to watch

The article lacks context on total insider holdings over time, whether other insiders sold/bought, and whether the sale coincided with scheduled liquidity needs.

Relevance 6/10Novelty 6/10Timing: Filed 2026-06-09; transaction dated 2026-06-05

Background

The article is an SEC EDGAR Form 4 insider transaction disclosure for Natera, Inc.

Company-level read

Ticker impact

$NTRANeutralMedium confidence
Context

Natera director Marcus Gail Boxer sold $2.39M of NTRA shares via open-market transactions disclosed on SEC Form 4.

Expected impact

Likely limited/short-lived impact; watch for follow-on insider activity or any concurrent company-specific news.

Evidence & confidence

This is a routine Form 4 insider transaction with no 10b5-1 plan stated and no accompanying fundamental update in the article.

Market effects

No direct sector read-across; this is company-specific insider activity.

None indicated.

None indicated.

Counterpoint

Director sales can be pre-planned for diversification or tax needs; without a stated 10b5-1 plan, the market may overinterpret intent.

Key entities

  • Natera, Inc.

    Company whose shares were sold by a director in the reported Form 4.

  • Marcus Gail Boxer

    Director who executed open-market sales totaling ~$2.39M.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$NTRAHigh

Why Natera (NTRA) Stock Is Up Today

Natera (NTRA) stock rose 2.2% after the FDA granted Breakthrough Device designation to its multi-cancer early detection assay. The assay showed promising performance data across 12 cancer types. The company's shares are up 74.9% year-to-date, trading near a 52-week high of $425.64. Natera plans a commercial launch in Japan in 2027 for its Signatera test, approved as a companion diagnostic for bladder cancer.

$NTRAHigh

Natera Receives FDA Breakthrough Device Designation for Multi-Cancer Early Detection Blood Test

Natera (NTRA) received FDA Breakthrough Device Designation for its multi-cancer early detection blood test, based on clinical data covering 12 cancer types. The designation accelerates regulatory review but does not guarantee approval. The test analyzes cell-free DNA to detect cancer signals and their likely origin. Natera aims to expand early cancer detection options, though clinical performance and benefits require further evaluation.